Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).
about
Statins and fibrates for preventing melanomaNiacin, an old drug with a new twistDiagnosis and management of the metabolic syndrome in obesityMetabolic syndrome, inflammation and atherosclerosisDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.An overview of cholesterol managementAmerican Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementDoes nicotinic acid (niacin) lower blood pressure?Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parametersCommentary: A new approach to atherogenic dyslipidemia.Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS).Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.Nicotinic acid: an old drug with a promising futureProlonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS studyEffects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis TreTreating the metabolic syndrome.The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.Dyslipidaemia in diabetic patients: time for a rethink.Metabolic syndrome management.Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.Dyslipidemia and cardiovascular risk: the importance of early prevention.The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover studyA new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.Therapies for diabetic dyslipidaemia.Important considerations for treatment with dietary supplement versus prescription niacin products.Lipid lowering therapy in type 2 diabetes.Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?Nicotinic acid: clinical considerations.Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.
P2860
Q24245521-F9F7C2E1-3261-4125-A59F-3F44B70A7228Q27002774-D236AFF0-0DE3-496A-987B-6D15A2708BEAQ28192856-99F7E5D7-3F6F-4DC3-B17C-15C401461F86Q28219348-D9E70CC0-9391-41A0-B593-D4EE9988AF82Q28222549-79674DB6-4265-42CE-8578-2108CBC14085Q30380628-8A7B8C6C-99CF-4429-9172-E605D1D86D3EQ33776194-F288E620-555E-4A26-B694-8F065C9AA57EQ33802196-94FB3ABE-B1EE-4025-83AF-A8ECD2F895ECQ33932198-853CBE08-B784-46E2-A48C-081F8353D013Q34081331-D2ACCEC5-21C4-4755-98B3-867166BB67AEQ34181381-C88CE224-3C67-4A76-9956-BCC607675285Q34894236-59AB56B5-1227-4D93-9486-5F4B0F7677F3Q35026444-3E5A1ED0-A0F6-47CF-9247-2F0620245204Q35440499-F8EE786E-A486-4126-8F21-B32D8291904EQ36102958-DC42719A-D8E4-486B-93D6-ECBB31EFF087Q36303713-F27040F1-6C01-40CF-95B7-D2B91C9E91A3Q36438737-5BF0F2B6-5CAC-4887-8930-008786ACC47DQ36497035-23A0791E-7739-482F-B927-07A16ACBF88AQ36536280-E4D09FEF-4B1A-4904-BA54-1EE1AC6FE6A9Q36803424-AE43E921-659C-408A-AA86-1820D069EF70Q36815978-64C085F4-BD06-468A-BE2C-65CBDA7B93F1Q36892498-593E11F8-3C29-465D-B59E-96A94CFA7AF7Q36909519-31DEBD6B-F8C5-4E49-9D7C-62E7E4B5314CQ36916909-B9E943B2-DEFA-48F1-AF9E-37097094756DQ36968971-DBBDAD3F-286E-4947-8EF8-9E33B1C9C8C4Q37126967-61EB1F2F-25E3-4D64-BDEF-CFC32E36594BQ37167555-E09F9455-78C6-40AB-9CE3-2B3E8BD1125CQ37311034-249C8B53-2D7B-48B4-83F1-E2B4F1B8B482Q37311116-9551177F-26EC-46A4-ACD9-42CED7462F77Q37458891-C2320FDF-C05E-42AB-AF7D-77D704026700Q37663503-EDC33163-B017-4078-94BD-ABCF25ABA305Q37689135-28CFA1F7-1A0D-4A1A-A26A-0FE2EF505F4BQ37825945-F414935A-7F9D-4658-8AB9-1E1983AB6A52Q37862929-F8D3D4F3-DC9D-4D3D-991F-371B7FDD0D09Q37902579-EC88235F-B692-480F-866A-B981D0110F4FQ37923968-4C9D62B5-136F-44FB-90AD-274A04D06B76Q37964753-4924567B-96A9-48F9-A937-4210F1B5D24BQ38008035-60B1215C-5628-402C-8D3A-8B2804039904Q38011204-E4DA4AB8-2E60-4B43-BC40-50ADA6698487Q38088216-CDCB316B-D8CF-4588-A3D7-0F3F10A0FE08
P2860
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Benefits of niacin by glycemic ...... om the Coronary Drug Project).
@en
Benefits of niacin by glycemic status in patients with healed myocardial infarction
@nl
type
label
Benefits of niacin by glycemic ...... om the Coronary Drug Project).
@en
Benefits of niacin by glycemic status in patients with healed myocardial infarction
@nl
prefLabel
Benefits of niacin by glycemic ...... om the Coronary Drug Project).
@en
Benefits of niacin by glycemic status in patients with healed myocardial infarction
@nl
P2093
P1476
Benefits of niacin by glycemic ...... om the Coronary Drug Project).
@en
P2093
Curt D Furberg
Mark E McGovern
Michael L Terrin
Paul L Canner
P304
P356
10.1016/J.AMJCARD.2004.09.013
P407
P577
2005-01-01T00:00:00Z